How many insider trades does FilingIQ track for ANL?

FilingIQ tracks 4 Form 4 insider transactions for ANL (Adlai Nortye Group Ltd.), covering filings from May 13, 2026 onwards. 3 of those were filed in the last 90 days.

Are ANL insiders net buyers or net sellers?

Across the full Form 4 history for ANL, 0 transactions (0%) were open-market purchases and 3 (75%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ANL insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ANL in?

Adlai Nortye Group Ltd. (ANL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $702.26M.

ANL insider trading

NasdaqGM Healthcare

Adlai Nortye Group Ltd. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 75%

Market cap

$702.26M

About Adlai Nortye Group Ltd.

Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas; AN4035, a proprietary CEACAM5-targeting antibody drug conjugate designed to deliver potent anti-tumor activity with an improved therapeutic window; and AN8025, a tri-specific antibody fusion protein which is in phase Ia clinical trial to treat advanced tumors. In addition, it develops AN4005, a small-molecule PD-L1 inhibitor that demonstrates antitumor activity by the blockade of PD-1/PD-L1 interaction which is in phase 1b clinical trial to activate cancer immunity. Further, the company is involved in technology transfer and consulting services business. Adlai Nortye Ltd. was founded in 2004 and is headquartered in North Brunswick, New Jersey.

Company website: www.adlainortye.com

ANL insider activity at a glance

FilingIQ has scored 4 insider transactions for ANL since May 13, 2026. The most recent filing in our index is dated Aug 26, 2026.

Across the full history, 0 open-market purchases and 3 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ANL insider trades is 66.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ANL trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 827

UNITED THERAPEUTICS Corp

BLLN 169

BillionToOne, Inc.

KYMR 167

Kymera Therapeutics, Inc.

Guardant Health, Inc.

OMDA 109

Omada Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for ANL?: FilingIQ tracks 4 Form 4 insider transactions for ANL (Adlai Nortye Group Ltd.), covering filings from May 13, 2026 onwards. 3 of those were filed in the last 90 days.
Are ANL insiders net buyers or net sellers?: Across the full Form 4 history for ANL, 0 transactions (0%) were open-market purchases and 3 (75%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ANL insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ANL in?: Adlai Nortye Group Ltd. (ANL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $702.26M.

Methodology & sources

Every ANL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.